This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Ondas (ONDS) Holdings priced its $425M underwritten offering of 19,560,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase up to 17,400,000 shares of its ...

Immediate liquidity and choice: The warrants are expected to be listed on Nasdaq under the symbols OPENW, OPENL, and OPENZ (subject to approval), so holders will be able to monetize the warrant right ...

MultiSensor AI Holdings, Inc. (NASDAQ: MSAI) ("MSAI," "we," "our" or the "Company"), a pioneer in AI-powered industrial ...

BOSTON, MASSACHUSETTS / ACCESS Newswire / October 6, 2025 / Ondas Holdings Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous aerial and ground robot intelligence and ...

Warrants to purchase 60,000 shares of common stock will be exercised at their existing exercise price of $2.00 per share, warrants to purchase 948,596 shares of common stock will be exercised at their ...

HENDERSON, Nev., Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an ...

LM Funding America (LMFA) entered into privately negotiated repurchase agreements with 7 institutional investors to acquire 3,308,575 shares of ...

HENDERSON, Nev., Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in ...

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- . (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic investments in companies in the junior resources and ...

REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel ...

REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody ...